Francesca L. R.
- Country
- Italy
- Department
- Medical Oncology
Research Overview
- Phase III Randomized Trial of Docetaxel plus Apalutamide Intensification in Metastatic Hormone-Sensitive Prostate Cancer with Inadequate PSA Response
- Phase 3 Randomized, Double-Blind Study of Niraparib, Abiraterone Acetate, and Prednisone in HRR Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer
Data & Insights
Has run more than one trial at 12 of 116 partner sites.
Specializations
Oncological Focus
This investigator specializes in treating metastatic castration-sensitive prostate cancer, with particular emphasis on cases involving homologous recombination repair (HRR) gene mutations.
- Prostate Cancer Treatment
- Genetic Mutation Analysis
- Metastatic Disease Management
The investigator's work encompasses both germline and somatic mutations in prostate cancer therapy.
Therapeutic Expertise
The investigator focuses on developing combination therapy approaches for advanced prostate cancer, particularly integrating novel therapeutic agents with established treatments.
- Combined Treatment Strategies
- Advanced Cancer Therapeutics
- Hormone-Sensitive Cancer Treatment
Their work involves evaluating therapeutic efficacy in hormone-sensitive cancer conditions.
Clinical Innovation
The investigator's expertise extends to evaluating progression-free survival in advanced prostate cancer patients through innovative treatment combinations.
- Treatment Response Assessment
- Patient Outcome Evaluation
- Therapeutic Innovation
Their focus includes investigating targeted therapeutic approaches for specific genetic profiles in cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.